Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01126268 · ClinicalTrials.gov registry record · Phase 4
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
A Phase 4 study of Impetigo and Folliculitis, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01126268: Completed Phase 4 study of Impetigo and Folliculitis, sponsored by The University of Texas Health Science Center, Houston.
NCT01126268 is a Phase 4 study of Impetigo and Folliculitis that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 38 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01126268, a Phase 4 study of Impetigo and Folliculitis, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections including secondarily infected eczema presumed to be caused by methicillin resistant Staph aureus. Male and female patients ages 9 months to 98 years will be recruited from a university based dermatology clinic. Upon enrollment, wound cultures will be collected, and then subjects will apply topical retapamulin twice daily for five days. The primary endpoint will be resolution of methicillin-resistant Staphylococcus aureus (MRSA) infection based on clinical presentation and physical exam, as well as bacteriological efficacy based on culture results. It is anticipated that approximately 75 patients will be enrolled, with expectation that approximately 50 of these patients will have MRSA infections.
Primary Outcome
Clinical success is defined as no further signs or symptoms of infection present, including erythema, purulence, crusting, edema, warmth and pain.
Conditions Studied
Interventions
- DRUG Retapamulin (Altabax)
Study Locations (1)
Texas
- Houston Medical Center Building - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-11 |
| Phase | Phase 4 |
What the finished NCT01126268 record still lists
NCT01126268 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Impetigo appearing as the primary indexed condition, and to 1 intervention - of which Retapamulin (Altabax) is the first listed.
NCT01126268 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01126268 about?
NCT01126268 is a clinical study titled "Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection". The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections including secondarily infected eczema presumed to be caused by methicillin resi...
What is the current status of trial NCT01126268?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2010-04. Estimated completion is 2012-11.
What conditions does trial NCT01126268 study?
This clinical trial studies the following conditions: Impetigo, Folliculitis, Secondarily Infected Eczema, Minor Soft Tissue Infections.
What interventions are being tested in trial NCT01126268?
The interventions under investigation include: Retapamulin (Altabax) (DRUG).
Who is sponsoring clinical trial NCT01126268?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01126268 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Impetigo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01126268's enrollment target sits among peer trials
38 1476th of 2000 higher than 519 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia